PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 193 filers reported holding PDL BIOPHARMA INC in Q4 2016. The put-call ratio across all filers is 0.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $207,000 | -0.5% | 71,071 | -3.9% | 0.30% | -11.0% |
| Q1 2020 | $208,000 | -21.5% | 73,950 | -9.6% | 0.34% | +43.0% |
| Q4 2019 | $265,000 | +65.6% | 81,794 | +10.7% | 0.24% | +34.3% |
| Q3 2019 | $160,000 | -9.1% | 73,910 | +32.2% | 0.18% | +92.3% |
| Q2 2019 | $176,000 | +57.1% | 55,911 | +86.5% | 0.09% | +54.2% |
| Q1 2019 | $112,000 | +28.7% | 29,977 | 0.0% | 0.06% | +9.3% |
| Q4 2018 | $87,000 | -55.6% | 29,977 | -59.9% | 0.05% | -40.0% |
| Q3 2018 | $196,000 | +23.3% | 74,695 | +10.0% | 0.09% | +32.4% |
| Q2 2018 | $159,000 | -53.1% | 67,892 | -41.2% | 0.07% | -43.8% |
| Q1 2018 | $339,000 | +26.5% | 115,431 | +18.1% | 0.12% | +33.0% |
| Q4 2017 | $268,000 | -28.0% | 97,777 | -11.0% | 0.09% | -24.8% |
| Q3 2017 | $372,000 | +30.1% | 109,818 | -5.1% | 0.12% | +36.0% |
| Q2 2017 | $286,000 | -0.7% | 115,683 | -8.7% | 0.09% | -1.1% |
| Q1 2017 | $288,000 | +89.5% | 126,771 | +76.7% | 0.09% | +95.7% |
| Q4 2016 | $152,000 | -43.1% | 71,728 | -9.9% | 0.05% | -44.6% |
| Q3 2016 | $267,000 | +27.8% | 79,589 | +19.5% | 0.08% | +13.7% |
| Q2 2016 | $209,000 | +25.1% | 66,608 | +32.7% | 0.07% | +10.6% |
| Q1 2016 | $167,000 | -6.2% | 50,198 | 0.0% | 0.07% | -33.3% |
| Q4 2015 | $178,000 | -36.4% | 50,198 | -9.9% | 0.10% | -42.8% |
| Q3 2015 | $280,000 | -27.8% | 55,694 | -7.7% | 0.17% | -23.1% |
| Q2 2015 | $388,000 | +12.8% | 60,336 | +23.2% | 0.22% | +27.1% |
| Q1 2015 | $344,000 | -9.0% | 48,968 | 0.0% | 0.18% | +21.2% |
| Q4 2014 | $378,000 | +75.8% | 48,968 | +69.8% | 0.15% | +71.8% |
| Q3 2014 | $215,000 | -25.9% | 28,847 | -3.6% | 0.08% | -24.1% |
| Q2 2014 | $290,000 | +110.1% | 29,933 | +80.5% | 0.11% | +93.1% |
| Q1 2014 | $138,000 | -91.5% | 16,585 | -91.4% | 0.06% | -93.1% |
| Q4 2013 | $1,626,000 | +34.0% | 192,605 | +26.6% | 0.84% | -11.1% |
| Q3 2013 | $1,213,000 | -4.2% | 152,157 | -7.2% | 0.95% | -9.3% |
| Q2 2013 | $1,266,000 | – | 163,984 | – | 1.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |